Hims & Hers Health (NYSE:HIMS) Stock Price Expected to Rise, Barclays Analyst Says

Key Points

• Barclays raised its price target on Hims & Hers from $25 to $29 and kept an "overweight" rating—implying roughly a 10.8% upside—while other firms have also lifted targets even as MarketBeat's consensus remains a "Hold" at $30.75.
• Novo Nordisk partnership cleared a legal overhang and enables Hims & Hers to sell FDA‑approved Ozempic/Wegovy on its platform, cited as a direct revenue and margin driver that has prompted analyst upgrades and bullish market interest.
• Hims & Hers beat Q4 EPS estimates ($0.08 vs. $0.02) but slightly missed revenue ($617.8M vs. $619.5M) with revenue up 28.4% YoY, and the board authorized a $250 million share buyback (about 3% of shares), signaling management confidence.

Hims & Hers Health (NYSE:HIMS - Get Free Report) had its target price increased by Barclays from $25.00 to $29.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm currently has an "overweight" rating on the stock. Barclays's target price would suggest a potential upside of 10.80% from the company's current price.

Other equities research analysts have also issued reports about the company. Bank of America raised Hims & Hers Health from an "underperform" rating to a "neutral" rating and increased their target price for the stock from $12.50 to $23.00 in a research report on Tuesday. Zacks Research raised shares of Hims & Hers Health from a "strong sell" rating to a "hold" rating in a report on Wednesday, February 25th. Weiss Ratings restated a "hold (c)" rating on shares of Hims & Hers Health in a research report on Monday, December 29th. Deutsche Bank Aktiengesellschaft lifted their price objective on shares of Hims & Hers Health from $25.00 to $28.00 and gave the company a "hold" rating in a research report on Tuesday. Finally, BTIG Research lowered shares of Hims & Hers Health from a "buy" rating to a "neutral" rating in a research note on Tuesday, February 24th. Three investment analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, Hims & Hers Health presently has a consensus rating of "Hold" and a consensus target price of $30.75.

Hims & Hers Health Stock Performance

HIMS stock traded up $2.70 during midday trading on Wednesday, reaching $26.17. The company had a trading volume of 51,621,830 shares, compared to its average volume of 33,284,391. The company has a quick ratio of 1.70, a current ratio of 1.90 and a debt-to-equity ratio of 1.80. The stock has a 50 day moving average price of $24.31 and a 200 day moving average price of $37.75. Hims & Hers Health has a fifty-two week low of $13.74 and a fifty-two week high of $70.43. The firm has a market capitalization of $5.97 billion, a PE ratio of 51.21, a P/E/G ratio of 4.24 and a beta of 2.55.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings results on Monday, February 23rd. The company reported $0.08 earnings per share for the quarter, topping analysts' consensus estimates of $0.02 by $0.06. The business had revenue of $617.82 million for the quarter, compared to analysts' expectations of $619.48 million. Hims & Hers Health had a return on equity of 22.48% and a net margin of 5.47%.The business's quarterly revenue was up 28.4% on a year-over-year basis. During the same period in the prior year, the firm earned $0.11 EPS. Analysts anticipate that Hims & Hers Health will post 0.29 earnings per share for the current year.

Hims & Hers Health declared that its board has approved a stock buyback plan on Monday, November 17th that authorizes the company to buyback $250.00 million in outstanding shares. This buyback authorization authorizes the company to reacquire up to 3% of its shares through open market purchases. Shares buyback plans are generally an indication that the company's management believes its shares are undervalued.

Insider Buying and Selling

In related news, insider Deborah M. Autor sold 7,054 shares of the business's stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total transaction of $258,952.34. Following the sale, the insider owned 6,175 shares of the company's stock, valued at $226,684.25. The trade was a 53.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Patrick Harrison Carroll sold 10,021 shares of the company's stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total value of $367,870.91. Following the completion of the sale, the insider owned 169,940 shares of the company's stock, valued at $6,238,497.40. This trade represents a 5.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 80,463 shares of company stock worth $2,846,696. Company insiders own 17.71% of the company's stock.

Institutional Trading of Hims & Hers Health

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Pathway Capital Management LP purchased a new stake in Hims & Hers Health during the third quarter valued at about $6,766,000. Steadview Capital Management LLC increased its position in shares of Hims & Hers Health by 80.0% in the third quarter. Steadview Capital Management LLC now owns 701,845 shares of the company's stock worth $39,809,000 after acquiring an additional 311,845 shares in the last quarter. State of Michigan Retirement System raised its holdings in shares of Hims & Hers Health by 49.2% during the third quarter. State of Michigan Retirement System now owns 2,057,700 shares of the company's stock valued at $116,713,000 after acquiring an additional 678,600 shares during the period. Carnegie Investment Counsel raised its holdings in shares of Hims & Hers Health by 25.4% during the third quarter. Carnegie Investment Counsel now owns 303,909 shares of the company's stock valued at $17,238,000 after acquiring an additional 61,560 shares during the period. Finally, BIT Capital GmbH lifted its position in shares of Hims & Hers Health by 73.8% in the 3rd quarter. BIT Capital GmbH now owns 2,210,384 shares of the company's stock valued at $125,373,000 after acquiring an additional 938,728 shares in the last quarter. Institutional investors own 63.52% of the company's stock.

Hims & Hers Health News Summary

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Strategic partnership with Novo Nordisk clears legal risk and enables HIMS to sell FDA‑approved Ozempic/Wegovy on its platform — a direct revenue driver and margin improver. Patience Pays: Hims & Hers Surges on News of Novo Nordisk Deal
• Positive Sentiment: Wave of analyst upgrades and price‑target increases (Needham, Barclays, Deutsche Bank, Citigroup, etc.) reflecting reduced legal risk and modeled GLP‑1 contribution. These upgrades support buy‑side interest. Barclays Raises Hims & Hers (HIMS) Target to $29 After Novo Deal Clears Legal Overhang
• Positive Sentiment: Unusually large call‑option activity (≈322k calls) indicates speculative/bullish positioning that can amplify upside momentum. Hims & Hers Health Target of Unusually Large Options Trading NYSE: HIMS
• Neutral Sentiment: Corporate hire: Kathryn Beiser named Chief Communications Officer to lead external/internal messaging as the company scales — supports investor communications but not an immediate revenue catalyst. Hims & Hers Names Kathryn Beiser as Chief Communications Officer
• Neutral Sentiment: Product/platform expansion: HIMS is broadening its digital care services (new specialties, lab testing, global rollout) — supports longer‑term revenue diversification but will take time to show measurable impact. Hims and Hers Expands Consumer-Focused Digital Health Platform
• Negative Sentiment: High short interest and squeeze dynamics create volatility risk — gains can be sharp but also susceptible to rapid reversals once speculative pressure eases. Hims & Hers Short Squeeze Is Looking Dangerous (Rating Downgrade)
• Negative Sentiment: Regulatory / litigation backdrop and ongoing investigations remain a watch item despite the Novo truce; Q4 showed an EPS beat but a slight revenue miss — execution and regulatory clarity仍 important. Hims & Hers Health Investigation Initiated

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients' doorsteps.

The company's product portfolio addresses key areas of men's and women's health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.